Supportive Care Flashcards

1
Q

CINV

A

increases morbidity
negatively effects patients QOL
non-adherence to chemo +/- dose reductions
weakness, dehydration, electrolyte imbalance, esophageal tears, decline in behavioral & mental status

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

acute CINV

A

occurring within first 24 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

delayed CINV

A

24 hours to several days (2-5 days) after chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

breakthrough CINV

A

occurs despite prophylactic treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

anticipatory CINV

A

before treatment as a conditioned response to the occurrence in previous cycles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

refractory CINV

A

recurring in subsequent cycles of therapy, excluding anticipatory CINV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

peripheral emetic response pathway

A

5HT3 mediated
originates in GI tract
activated in first 24 hours after chemo
associated with acute emesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

central emetic response pathway

A

NK1 receptor mediated
primarily in the brain
involved in delayed CINV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

general principles of emesis control

A

prevention!
choosing antiemetic agents: emetic risk, prior experience with antiemetics, patient factors
prophylaxis based on agent with the highest emetogenic risk
lifestyle management: smaller more frequent meals, healthier meals, room temperature food

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

risk factors of CINV

A

<50 yo
emesis during pregnancy
history of CINV, prone to motion sickness
female sex
little/no previous alcohol use
anxiety/ high pretreatment expectations of nausea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

high IV emetogenic potential

A

AC ( anthracycline + cyclophosphamide)
carboplatin >4
Carmustine
Cisplatin
Cyclophosphamide
Dacarbazine
Doxorubicin
Epirubicin
Fam-trastuzumab deruxtecan
Ifosfamide
Mechlorethamine
Melphalan
Sacituzumab
Streotozocin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

oral agents prophylaxis required on days of chemo admin

A

azacitidine
busulfan
certinib
cyclophosphamide
fedratinib
lomustine
midostaurin
mitotane
selinexor
temozolomide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

breakthrough emesis treatment

A

add one agent from a different drug class
consider routine admin vs PRN
antacid therapy if patient has dyspepsia
*olanzapine, lorazepam, dronabinol, 5HT3 RA, prochloperazine, dexamethasone, metoclopramide, scopolamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

anticipatory emesis treatment

A

prevention!
avoid strong smells
Lorazepam useful
acupuncture
behavioral therapy: guided imagery, relaxation, hypnosis, cognitive distraction, yoga, biofeedback, progressive muscle relaxation,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Dexamethasone

A

MOA unknown
ADEs:
Insomnia- admin in morning
dyspepsia: take with food, consider H2 antagonist or PPI
Hyperglycemia
Hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

5HT3 RA (ondansetron, palonosetron, granisetron)

A

MOA: blocks serotonin peripherally (GI tract) on vagal nerve terminals and centrally in the chemoreceptor trigger zone (medulla)
1st gen: ondansetron, granisetron
-most effective for acute
-short acting
2nd gen: palonosetron
-effective in acute & delayed
-long acting

ADES:
headache
constipation
QTc prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

NK1 RA (aprepitant, fosaprepitant, rolapitant, fosnetupitant/palonestron, netupitant/ palonestron)

A

MOA: inhibits the substance P/ neurokinin 1
-augments 5HT3 & dexamethasone antiemetic activity
Only for prevention not treatment
-most useful delayed CINV
Drug interactions (except rolapitant)
-inhibition of CYP3A4 and CYP2C9 (decrease dexamethasone dose on days 2-4)
ADEs: fatigue, GI upset, headache, hiccups

Rolapitant has extended half life should not admin <2 wk intervals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Olanzapine

A

MOA: blocks dopamine, 5HT3, muscarinic and histamine receptors
Useful in prevention and breakthrough

ADES;
sedation: admin at bedtime, consider low dose for elderly
Hyperglycemia
Fatigue
QTc prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Dopamine antagonists (prochlorperazine, metoclopramide, promethazine)

A

MOA: antagonize dopamine in the chemoreceptor trigger zone
Breakthrough CINV

Prochlorperazine, Promethazine
-phenothiazines
-drowsiness
-constipation

Metoclopramide
-benzamines
-drowsiness
-diarrhea
-QTc prolongation
-tardive dyskinesia (avoid >12wks)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Benzodiazepines (lorazepam)

A

MOA: anxiolytic
Useful for anticipatory or breakthrough with anxiety component
ADMIN either night before, morning of or both
ADES;
sedation
dizziness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Cannabinoids

A

MOA: CB1 agonism suppresses vomiting
indirect activation of 5HT1a in raphe nucleus
Only for refractory disease
ADEs: sedation, euphoria, hallucinations, palpitations, flushing, cough

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Scopolamine

A

MOA: anticholinergic
Breakthrough only
ADE: dry mouth, somnolence, blurred vision

23
Q

CTID

A

incidence as high as 50-80%
depletion of fluids and electrolytes, malnutrition, dehydration and hospitalization, death
dose delays or reductions
Offenders: flurouracil, capecitabine, irinotecan, pertuzumab, abemaciclib)

24
Q

assessment of CTID

A

history
volume and duration
hydration status
added risk factors: fever, orthostatic symptoms, abdominal pain/ cramping, weakness

25
Irinotecan- induced diarrhea
irinotecan can cause acute or delayed diarrhea acute: -due to cholinergic stimulation -mean duration ~30mind -usually respond rapidly to atropine delayed: -due to GI mucosal damage secondary to SN-38 -usually occurs >24 hours after admin -noncumulative and occurs at all dose levels
26
management of CTID
Nonpharm: -avoidance of foods that aggravate diarrhea -aggressive oral rehydration with fluids that contain water, salt, and sugar Pharm: -loperamide: first line, 4mg followed by 2mg q 4hours or after every unformed stool (max 16mg) -diphenoxylate-atropine: 1-2 tabs q 6hours until control achieved (max 8 tabs)
27
refractory CTID
octreotide tincture of opium probiotics rule out clostridiolides difficile and infection colitis
28
mucositis
occurs in 20-40% of patients Onset: 5-14 days Complications: decreased oral intake: poor nutritional status Grade 3-severe oral pain Grade 4- requires parenteral or enteral nutrition Infection Risk: gram positive oral flora, candida or fungal infections Pain: may require opioids and PCA admin
29
mucositis definition
erythematous and ulcerative lesions of the mucosa observed in patients treated with chemo can occur anywhere in the GI tract
30
stomatitis definition
mucositis limited to the oral cavity
31
5 stage model of oral mucositis
initiation: cellular damage induces, reactive oxygen species formation primary damage response: activation of p53 & NF-kB signal amplification: release of inflammatory cytokines, tissue damage and cell death ulceration: high risk for bacterial colonization healing: cessation from ongoing tissue damage
32
Chemo risk factors for mucositis
melphalan cisplatin + radiation high dose methotraxate doxorubicin busulfan 5-FU
33
patient risk factors for mucositis
smoking poor oral hygiene oral lesions at baseline female sex pretreatment nutritional status
34
grade 1 mucositis
asymptomatic or mild symptoms intervention not indicated
35
grade 2 mucositis
moderate pain or ulcer that does not interfere with oral intake modified diet indicated
36
grade 3 mucositis
severe pain interfering with oral intake
37
grade 4 mucositis
life threatening consequences urgent intervention indicated
38
prevention of chemo induced mucositis
oral hygiene cryotherapy
39
management of mucositis
oral decontamination: bland or oncology mouthwash, dexamethasone for everlimus-induced pain control: 2% lidocaine, systemic opioids palliation of dry mouth: artificial saliva products or chewing gum nutritional support: liquid or soft diet; TPN oral candidiasis treatment: fluconazole 200mg x1, then 100mg x 21 days
40
patient risk factors for febrile neutropenia
prior chemotherapy or radiation therapy persistent neutropenia bone marrow involvement by tumor recent surgery and/or open wounds liver dysfunction renal dysfunction >65 yo full dose chemo
41
filgrastim
short acting GCSF start next day or up to 3-4 days after completion of chemo (5mcg/kg) given until ANC recovery
42
Pegfilgrastim
long acting GCSF can admin day after or up to 3-4 days after completion of chemo single admin(6mg) allow >12 days between dose of pegfilgrastim and next cycle of chemo
43
eflapegrastim or efbemalengrastim
long acting GCSF admin 24 hours after chemo single admin do not administer 14 days before and within 24 hours of chemo
44
possible indications for GCSF use in established febrile neutropenia
sepsis syndrome >65 yo ANC <100 neutropenia expected to be >10 days in duration pneumonia or other clinically documented infections invasive fungal infection hospitalization at time of fever prior episode of febrile neutropenia
45
somatic pain
tumor invades bone, muscle, or connective tissue often presented as aching, stabbing, throbbing or pressure
46
visceral pain
tumor invades internal organs and blood vessels often presented as gnawing, cramping, aching, or sharp pain
47
neuropathic pain
pain sustained by damage or dysfunction in the nervous system often presented as burning tingling shooting or electric/shocking pain
48
general principles of opioids
offer to patients with moderate to severe pain lowest possible dose to achieve acceptable analgesia start with immediate release and PRN with frequent assessment and titration PRN -breakthrough pain -IR or short acting opioid Around the clock -treat chronic pain -SR or long acting opioids
49
immune related adverse events
increased immune system activity from ICI results in inflammatory side effects -increased t cell activity, preexisting autoantibodies, inflammatory cytokines can occure during or after discontinuation on ICI treatment make note of history of autoimmune disease
50
mild-moderate AEs of immune mediated
symptomatic management local therapies preferred consider delaying immunotherapy corticosteroids may be required
51
severe aes immune mediated
hold immunotherapy corticosteroids required possible additional immunosuppressant in steroid refractory AEs inpatient managemnet and addition supportive care may be necessary
52
corticosteroids Immune mediated AEs
dose varies based on severity -prednisone 0.5-2mg/kg/day -methylprednisolone 1-2 mg/kg/day prolonged steroid taper (4-12 weeks) may be required long term use associated with HTN, osteoporosis, weight gain, insomnia, mental status changes, metabolic dysfunction, increased infection risk
53
corticosteroid supportive care
Gastritis: -PPI or H2 blocker in high risk (NSAID use, anticoagulation) for duration of corticosteroids Infection -PJP prophy: prednisone equivilant >20mg for >4 weeks : trimethoprim/sulfamethoxazole preferred -Fungal: prednisone equivalent >20mg for 6-8 weeks : fluconazole Osteoporosis -Vit D 400-1000 IU daily and calcium 1000-1200mg from food or supplementation